Method of and vaginal insert for prostaglandin administration

Claim 2

A vaginal device adapted for insertion and placement in the female human vaginal cavity and subsequent removal therefrom, for the administration of an abortifacient or oxytocic prostaglandin to the epithelial tissues of said cavity, said device consisting essentially of a flexible resilient non-toxic polysiloxane elastomer substantially uniformly impregnated except at the elastomer surface with at least an effective amount of said absortifacient prostaglandin to accomplish an abortion in a human during the first or second trimester or pregnancy or with at least an effective amount of said oxytocic prostaglandin to accomplish the induction of labor in a pregnant human at or near term, said prostaglandin being present in free acid form or in a more lipophilic ester form, said device having two substantially parallel relatively large elastomer surfaces with combined surface area at least 70 percent of the total elastomer surface area of the device, both of said parallel elastomer surfaces providing means for assuming a contour to be in substantial contact with the vaginal epithelial tissue, there being substantially no prostaglandin at said parallel elastomer surfaces of said device prior to vaginal insertion, the combination of the total elastomer surface area of said device and the concentration of prostaglandin in said device constituting a means for providing a medically acceptable release rate of said prostaglandin in the human vagina to accomplish said abortion of said induction of labor, and the combination of the resilience of said elastomer and the distance between said parallel elastomer surfaces being such that both of said parallel elastomer surfaces remain either in contact with said epithelial tissues or exposed to the fluids in said vaginal cavity when said device is in the vaginal cavity.

Claim 3

A device according to claim 1 wherein said prostaglandin is an abortifacient prostaglandin.

Claim 4

A device according to claim 2 wherein the two sustantially parallel relatively large elastomer surfaces have a combined surface area at least 85 percent of the total elastomer surface area of the device.

Claim 5

A device according to claim 3 wherein the parallel large elastomer surfaces are substantially planar.

Claim 6

A device according to claim 4 wherein the polysiloxane elastomer is a dimethylpolysiloxane.

Claim 7

A device according to claim 5 wherein the dimethylpolysiloxane elastomer is the type which is prepared by catalytic polymerization of the liquid dimethylpolysiloxane prepolymer in the range about 20°-40° C.

Claim 8

A device according to claim 6 wherein the abortifacient prostaglandin is of the PGF.sub.α -type and is present in the device in an amount about 2 to about 10 times the amount effective to accomplish an abortion in a human during the first or second trimester of pregnancy.

Claim 9

A device according to claim 7 wherein said prostaglandin is a methyl or ethyl ester.

Claim 10

A device according to claim 8 wherein said prostaglandin is (15S)-15-methyl-PGF 2 α methyl ester.

Claim 11

A device according to claim 9 wherein the combined surface area of the two parallel large surfaces is in the range 10-50 square centimeters.

Claim 12

A device according to claim 9 wherein the prostaglandin is present in a concentration range 0.1-3%.

Claim 13

A device according to claim 9 wherein the prostaglandin is present in a concentration range 0.2-1.5%.

Claim 14

A device according to claim 9 wherein the distance between the parallel relatively large elastomer surfaces is in the range 0.05 to 0.5 centimeters.

Claim 15

A vaginal device adapted for insertion and placement in the female human vaginal cavity and subsequent removal therefrom, for the administration of an abortifacient or oxytocic prostaglandin to the epithelial tissues of said cavity, said device consisting essentially of a laminate having two substantially parallel relatively large surfaces with combined surface area at least 70 percent of the total surface area of the device, both of said parallel elastomer surfaces providing means for assuming a contour to be in substantial contact with the vaginal epithelial tissue, said device having a layer consisting essentially of a flexible resilient non-toxic polymeric solid substantially free of prostaglandin, with a shape and surfaces substantially the same as said device but with total linear dimensions smaller than those of said devices, said solid bonded on one or both of its relatively large parallel surfaces or on all of its surfaces to a coextensive layer of a flexible resilient non-toxic polysiloxane elastomer substantially uniformly impregnated except at the outer elastomer surface with a total of at least an effective amount of said abortifacient prostaglandin to accomplish an abortion in a human during the first or second trimester of pregnancy or of at least an effective amount of said oxytocic prostaglandin to accomplish the induction of labor in a pregnant human at or near term, said prostaglandin being present in free acid form or in a more lipophilic ester form, there being substantially no prostaglandin at the outer elastomer surfaces prior to vaginal insertion, the combination of the total outer elastomer surface area of said device and the total concentration of prostaglandin in said elastomer constituting a means for providing medically acceptable release rate of said prostaglandin in the human vagina to accomplish said abortion or said induction of labor, the resilience of said device being such that the elastomer on one or both of said parallel surfaces of said device is either in contact with said epithelial tissues or exposed to the fluids in said vaginal cavity when said device is in said vaginal cavity.

Claim 16

A vaginal device adapted for insertion and placement in the female human vaginal cavity and subsequent removal therefrom, for the administration of an abortifacient or oxytocic prostaglandin to the epithelial tissues of said cavity, said device consisting essentially of a laminate having two substantially parallel relatively large surfaces with combined surface area at least 70 percent of the total surface area of the device, both of said parallel elastomer surfaces providing means for assuming a contour to be in substantial contact with the vaginal epithelial tissue, said device having a layer consisting essentially of a flexible resilient non-toxic polymeric solid substantially free of prostaglandin, with a shape and surfaces substantially the same as said device but with total linear dimensions smaller than those of said devices, said solid bonded on one or both of its relatively large parallel surfaces or on all of its surfaces to a coextensive layer of a flexible resilient non-toxic polysiloxane elastomer substantially uniformly impregnated except at the outer elastomer surface with a total of at least an effective amount of said abortifacient prostaglandin to accomplish an abortion in a human during the first or second trimester of pregnancy or of at least an effective amount of said oxytocic prostaglandin to accomplish the induction of labor in a pregnant human at or near term, said prostaglandin being present in free acid form or in a more lipophilic ester form, there being substantially no prostaglandin at the outer elastomer surfaces prior to vaginal insertion, the combination of the total outer elastomer surface area of said device and the total concentration of prostaglandin in said elastomer constituting a means for providing medically acceptable release rate of said prostaglandin in the human vagina to accomplish said abortion or said induction of labor, the resilience of said device being such that the elastomer on one or both of said parallel surfaces of said device is either in contact with said epithelial tissues or exposed to the fluids in said vaginal cavity when said device is in said vaginal cavity.

Claim 17

A device according to claim 14 wherein said prostaglandin is an abortifacient prostaglandin.

Claim 18

A device according to claim 15 wherein the flexible resilient non-toxic polymeric solid is the same polysiloxane elastomer to which said polymeric solid is bonded.

Claim 19

A device according to claim 15 wherein the flexible resilient non-toxic polymeric solid is a water-permeable water-insoluble gelatin sponge.

Claim 20

A device according to claim 17 wherein the gelatin sponge layer is bonded on both of its relatively large parallel surfaces to a coextensive layer of the prostaglandin-impregnated polysiloxane elastomer.

Claim 21

A device according to claim 18 wherein surfaces of the device other than the relatively large parallel surfaces are not bonded to the polysiloxane elastomer.

Claim 22

A device according to claim 19 wherein the two substantially parallel relatively large elastomer surfaces have a combined surface area at least 85 percent of the total surface area of the device.

Claim 23

A device according to claim 20 wherein the substantially parallel relatively large elastomer surfaces are substantially planar.

Claim 24

A device according to claim 21 wherein the polysiloxane elastomer is a dimethylpolysiloxane.

Claim 25

A device according to claim 22 wherein the dimethylpolysiloxane elastomer is the type which is prepared by catalytic polymerization of the liquid dimethylpolysiloxane prepolymer in the range about 20°-40° C.

Claim 26

A device according to claim 23 wherein the abortifacient prostaglandin is of the PGF.sub.α -type and is present in the device in an amount about 2 to about 10 times the amount effective to accomplish an abortion in a human during the first or second trimester of pregnancy.

Claim 27

A device according to claim 24 wherein said prostaglandin is a methyl or ethyl ester.

Claim 28

A device according to claim 25 wherein said prostaglandin is (15S)-15-methyl-PGF 2 α methyl ester.

Claim 29

A device according to claim 26 wherein the combined surface area of the two parallel large surfaces is in the range 10-50 square centimeters.

Claim 30

A device according to claim 2 wherein said prostaglandin has a potency in the golden hamster pregnancy test at least equal to that of PGE 2 .

Claim 31

A device according to claim 2 wherein said prostaglandin has a potency in the golden hamster pregnancy test at least 10 times that of PGE 2 .

Claim 32

A device according to claim 2 wherein said prostaglandin has a potency in the golden hamster pregnancy test at least 100 times that of PGE 2 .

Claim 33

A device according to claim 15 wherein said prostaglandin has a potency in the golden hamster pregnancy test at least equal to that of PGE 2 .

Claim 34

A device according to claim 15 wherein said prostaglandin has a potency in the golden hamster pregnancy test at least 10 times that of PGE 2 .

Claim 35

A device according to claim 15 wherein said prostaglandin has a potency in the golden hamster pregnancy test at least 100 times that of PGE 2 .

Claim 36

A method of accomplishing an abortion in a female human during the first and second trimester of pregnancy which comprises inserting a device according to claim 2 into the vaginal cavity of said human.

Claim 37

A method of accomplishing an abortion in a female human during the first and second trimester of pregnancy which comprises inserting a device according to claim 9 into the vaginal cavity of said human.

Claim 38

A method of accomplishing an abortion in a female human during the first or second trimester of pregnancy which comprises inserting a device according to claim 15 into the vaginal cavity of said human.

Claim 39

A method of accomplishing an abortion in a female human during the first or second trimester of pregnancy which comprises inserting a device according to claim 26 into the vaginal cavity of said human.

Claim 40

A method of accomplishing an abortion in a female human during the first and second trimester of pregnancy which comprises inserting a device according to claim 28 into the vaginal cavity of said human.

Claim 41

A method of accomplishing an abortion in a female human during the first or second trimester of pregnancy which comprises inserting a device according to claim 29 into the vaginal cavity of said human.

Claim 42

A method of accomplishing an abortion in a female human during the first or second trimester of pregnancy which comprises inserting a device according to claim 30 into the vaginal cavity of said human.

Claim 43

A method of inducing menstruation in a sexually exposed female human capable of ovulation, which comprises inserting a device according to claim 2 into the vaginal cavity of said human at a time after the time of expected but missed menses.

Claim 44

A method according to claim 41 wherein said device is inserted at a time at least two weeks after the time of expected but missed menses.

Claim 45

A method of inducing menstruation in a sexually exposed female human capable of ovulation, which comprises inserting a device according to claim 9 into the vaginal cavity of said human at a time after the time of expected but missed menses.

Claim 46

A method according to claim 43 wherein said device is inserted at a time at least two weeks after the time of expected but missed menses.

Claim 47

A method of inducing menstruation in a sexually exposed female human capable of ovulation, which comprises inserting a device according to claim 15 into the vaginal cavity of said human at a time after the time of expected but missed menses.

Claim 48

A method according to claim 45 wherein said device is inserted at a time at least two weeks after the time of expected but missed menses.

Claim 49

A method of inducing menstruation in a sexually exposed female human capable of ovulation, which comprises inserting a device according to claim 26 into the vaginal cavity of said human at a time after the time of expected but missed menses.

Claim 50

A method according to claim 47 wherein said device is inserted at a time at least two weeks after the time of expected but missed menses.

Claim 51

A method of inducing menstruation in a sexually exposed female human capable of ovulation, which comprises inserting a device according to claim 28 into the vaginal cavity of said human at a time after the time of expected but missed menses.

Claim 52

A method according to claim 49 wherein said device is inserted at a time at least two weeks after the time of expected but missed menses.

Claim 53

A method of inducing menstruation in a sexually exposed female human capable of ovulation, which comprises inserting a device according to claim 29 into the vaginal cavity of said human at a time after the time of expected but missed menses.

Claim 54

A method according to claim 51 wherein said device is inserted at a time at least two weeks after the time of expected but missed menses.

Claim 55

A method of inducing menstruation in a sexually exposed female human capable of ovulation, which comprises inserting a device according to claim 30 into the vaginal cavity of said human at time after the time of expected but missed menses.

Claim 56

A method according to claim 53 wherein said device is inserted at a time at least two weeks after the time of expected but missed menses.

Claim 57

A method of inducing menstruation in a sexually exposed female human capable of ovulation, which comprises inserting a device according to claim 31 into the vaginal cavity of said human at a time after the time of expected but missed menses.

Claim 58

A method according to claim 55 wherein said device is inserted at a time at least two weeks after the time of expected but missed menses.

Claim 59

A method of inducing menstruation in a sexually exposed female human capable of ovulation, which comprises inserting a device according to claim 32 into the vaginal cavity of said human at a time after the time of expected but missed menses.

Claim 60

A method according to claim 57 wherein said device is inserted at a time at least two weeks after the time of expected but missed menses.

Claim 61

A method of inducing menstruation in a sexually exposed female human capable of ovulation, which comprises inserting a device according to claim 33 into the vaginal cavity of said human at a time after the time of expected but misses menses.

Claim 62

A method according to claim 59 wherein said device is inserted at a time at least two weeks after the time of expected but missed menses.

Claim 63

A method emptying the uterus of a human female when said uterus contains a dead fetus, a hydatidiform mole, or a combination of those, which comprises inserting a device according to claim 2 into the vaginal cavity of said human.

Claim 64

A method of emptying the uterus of a human female when said uterus contains a dead fetus, a hydatidiform mole, or a combination of those, which comprises inserting a device according to claim 9 into the vaginal cavity of said human.

Claim 65

A method of emptying the uterus of a human female when said uterus contains a dead fetus, a hydatidiform mole, or a combination of those, which comprises inserting a device according to claim 15 into the vaginal cavity of said human.

Claim 66

A method of emptying the uterus of a human female when said uterus contains a dead fetus, a hydatidiform mole, or a combination of those, which comprises inserting a device accoring to claim 26 into the vaginal cavity of said human.

Claim 67

A method of emptying the uterus of a human female when said uterus contains a dead fetus, a hydatidiform mole, or a combination of those, which comprises inserting a device according to claim 28 into the vaginal cavity of said human.

Claim 68

A method of emptying the uterus of a human female when said uterus contains a dead fetus, a hydatidiform mole, or a combination of those, which comprises inserting a device according to claim 29 into a vaginal cavity of said human.

Claim 69

A method of emptying the uterus of a human female when said uterus contains a dead fetus, a hydatidiform mole, or a combination of those, which comprises inserting a device according to claim 30 into the vaginal cavity of said human.

Claim 70

A method of emptying the uterus of a human female when said uterus contains a dead fetus, a hydatidiform mole, or a combination of those, which comprises inserting a device according to claim 31 into the vaginal cavity of said human.

Claim 71

A method of emptying the uterus of a human female when said uterus contains a dead fetus, a hydatidiform mole, or a combination of those, which comprises inserting a device according to claim 32 into the vaginal cavity of said human.

Claim 72

A method of emptying the uterus of a human female when said uterus contains a dead fetus, a hydatidiform mole, or a combination of those, which comprises inserting a device according to claim 33 into the vaginal cavity of said human.

Claim 73

A method of accomplishing an abortion in a female human during the first or second trimester of pregnancy which comprises inserting a device according to claim 31 into the vaginal cavity of said human.

Claim 74

A method of accomplishing an abortion in a female human during the first or second trimester of pregnancy which comprises inserting a device according to claim 32 into the vaginal cavity of said human.

Claim 75

A method of accomplishing an abortion in a female human during the first or second trimester of pregnancy which comprises inserting a device according to claim 33 into the vaginal cavity of said human.